UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.44 USD
-0.04 (-2.70%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $1.44 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
UNITY Biotechnology, Inc. [UBX]
Reports for Purchase
Showing records 41 - 60 ( 102 total )
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Eyes on 16wk Ph2 ENVISION Data for UBX1325/wAMD in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
UBX1325 wAMD Data on 1Q23 Horizon, Adjustments With Reverse Split; PT Down to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Single IVT UBX1325 Supports Durable 24-Week Visual Acuity, Structural Benefits; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Positive 24-wk Results for UBX1325/DME Are a Sight to BEHOLD
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Adjusting Price Target, Reflecting Share Issuance and Reverse Share Split
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
BEHOLD! The Future of the Vitreoretinal Disease Paradigm; Analyst Day Takeaways
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
KOL Perspective-Setting UBX1325 Expectations in DME and wAMD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Enrollment Completed in Ph2 ENVISION Trial for UBX1325/ wAMD; 16wk Data in Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Cash Overhang Lifted; Runway Extends to Key Catalyst Readouts in 2022-23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
BEHOLD-Single UBX1325 IVT Injection Demonstrates Phase 2 DME Benefit; Reit. Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Company: UNITY Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Exceeds Expectations at 12 & 18wk in Ph2 BEHOLD Trial; Q2 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A